Latest Technology Platform News

Proteomics International secures half a million dollars from the Western Australian Government to accelerate commercialisation of PromarkerEndo, a groundbreaking blood test for early endometriosis diagnosis.

Cluey Ltd announces a strategic acquisition of tutoring provider Art of Smart, backed by a fully underwritten $4.5 million entitlement offer. The deal aims to expand Cluey’s omnichannel learning services and drive scalable growth.

4DMedical has responded to ASX queries over its FY2025 financial report, clarifying assumptions behind intangible asset valuations and addressing the auditor’s qualified opinion.

Linius Technologies has implemented a sweeping operational restructure, cutting expenses by more than 60% compared to FY25, while progressing a pivotal proof of concept with a major European football league and securing over $3.7 million in new funding.

Mad Paws Holdings reported a robust September quarter with 14% revenue growth and a successful divestment of Pet Chemist, while advancing its acquisition scheme with Rover Group.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

Catapult Sports has completed its acquisition of IMPECT GmbH, a leader in soccer scouting analytics, enhancing its technology suite with proprietary data insights.

Humm Group reports a 14% decline in new loan originations for 1Q26, driven by a steep 61% fall in Australian Point of Sale volumes following regulatory changes and technology setbacks. However, international growth and asset expansion provide some offset.

RemSense Technologies has secured major contracts with Shell, Chevron, and ExxonMobil while advancing its digital twin platform and recurring revenue base, setting the stage for growth despite near-term cash flow pressures.

Impact Minerals secures an 80% stake in the Lake Hope High Purity Alumina project following a robust Pre-Feasibility Study, while progressing pilot plant commissioning and a strategic joint venture in NSW.

Noxopharm Limited reports growing interest in its Sofra technology with new research collaborations and a safe, well-tolerated HERACLES trial of SOF-SKN. The company also secures funding extensions to support ongoing development.

Betr Entertainment Limited reported a strong start to FY26 with a 10.5% net win margin and 27% turnover growth, supported by significant marketing investments and product innovation.